CRS Clinical Research Services Management GmbH

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)3 trials
• Psoriasis3 trials
• Chronic kidney disease1 trial
• High blood pressure1 trial
• Stroke1 trial
• Tuberculosis1 trial
• Vitiligo1 trial

Phase

• Phase 35 trials
• Phase 14 trials
• Phase 21 trial

Status

• Completed7 trials
• Active, not recruiting3 trials

Lead sponsor

• Amgen Inc.2 trials
• Bayer1 trial
• Bayer AG1 trial
• BioNTech SE1 trial
• Bluefin Biomedicine Inc.1 trial
• and 4 more

Running trials

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

  NCT06220604· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Plaque Psoriasis Involving Special Areas

  2023-505122-34-00· Phase 3· Janssen - Cilag International· Source

• Active, not recruiting

  A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

  NCT06072183· Phase 3· Pfizer· Source

Closed trials

• Completed

  A Study Evaluating BFB759 in Atopic Dermatitis

  2025-521624-30-00· Phase 2· Bluefin Biomedicine Inc.· Source

• Completed

  A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure

  NCT06428825· Phase 1· Bayer· Source

• Completed

  A study to learn about the amount of asundexian in the blood when healthy participants take different types of asundexian tablets

  2023-509447-28-00· Phase 1· Bayer AG· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Completed

  A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.

  NCT06143371· Phase 1· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon)

  2022-501538-44-00· Phase 3· Amgen Inc.· Source

• Completed

  Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers

  NCT05537038· Phase 1· BioNTech SE· Source